Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance.

TitleSimultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance.
Publication TypeJournal Article
Year of Publication2018
AuthorsNakanishi Y, Duran A, L'Hermitte A, Shelton PM, Nakanishi N, Reina-Campos M, Huang J, Soldevila F, Baaten BJG, Tauriello DVF, Castilla EA, Bhangoo MS, Bao F, Sigal D, Diaz-Meco MT, Moscat J
JournalImmunity
Volume49
Issue6
Pagination1132-1147.e7
Date Published2018 12 18
ISSN1097-4180
KeywordsAdult, Aged, Aged, 80 and over, Animals, B7-H1 Antigen, CD8-Positive T-Lymphocytes, Cell Transformation, Neoplastic, Colorectal Neoplasms, Female, Humans, Immunologic Surveillance, Intestinal Mucosa, Intestinal Neoplasms, Isoenzymes, Male, Mice, Knockout, Mice, Transgenic, Middle Aged, Protein Kinase C, Receptors, Transforming Growth Factor beta
Abstract

Serrated adenocarcinoma, an alternative pathway for colorectal cancer (CRC) development, accounts for 15%-30% of all CRCs and is aggressive and treatment resistant. We show that the expression of atypical protein kinase C ζ (PKCζ) and PKCλ/ι was reduced in human serrated tumors. Simultaneous inactivation of the encoding genes in the mouse intestinal epithelium resulted in spontaneous serrated tumorigenesis that progressed to advanced cancer with a strongly reactive and immunosuppressive stroma. Whereas epithelial PKCλ/ι deficiency led to immunogenic cell death and the infiltration of CD8 T cells, which repressed tumor initiation, PKCζ loss impaired interferon and CD8 T cell responses, which resulted in tumorigenesis. Combined treatment with a TGF-β receptor inhibitor plus anti-PD-L1 checkpoint blockade showed synergistic curative activity. Analysis of human samples supported the relevance of these kinases in the immunosurveillance defects of human serrated CRC. These findings provide insight into avenues for the detection and treatment of this poor-prognosis subtype of CRC.

DOI10.1016/j.immuni.2018.09.013
Alternate JournalImmunity
PubMed ID30552022
PubMed Central IDPMC6301096
Grant ListR01 CA192642 / CA / NCI NIH HHS / United States
R01 CA218254 / CA / NCI NIH HHS / United States
R01 CA172025 / CA / NCI NIH HHS / United States
P30 CA030199 / CA / NCI NIH HHS / United States
R01 CA207177 / CA / NCI NIH HHS / United States
Related Faculty: 
Maria Diaz-Meco Conde, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700